# E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer

> **NCT01355302** · PHASE1,PHASE2 · TERMINATED · sponsor: **Eisai Inc.** · enrollment: 7 (actual)

## Conditions studied

- Advanced or Metastatic Solid Tumors
- Previously Untreated Gastric Cancer

## Interventions

- **DRUG:** E7050
- **DRUG:** cisplatin
- **DRUG:** capecitabine

## Key facts

- **NCT ID:** NCT01355302
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-11
- **Primary completion:** 2013-04
- **Final completion:** 2013-07
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Sites not recruiting
- **Last updated:** 2017-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01355302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01355302, "E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01355302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*